Daily FNArena News - Australia

Australia’s lottery market is worth $3.6bn a year but only 4% of punters play online. Manaccom is well established to take advantage of inevitable growth.

A snapshot of economist responses to today’s CPI release.

Mesoblast has been recording good Phase II trials results in bone marrow transplantation and Southern Cross Equities suggests this could make it a target of Big Pharma.

Following recent exploration disappointment, Woodside’s plan for a second LNG train at Pluto is running out of time. Browse and Sunrise are further away still. Can Woodside deliver on its potential?

June quarter retail sales numbers for Wesfarmers were solid, the key Coles business delivering a good result and offering evidence the turnaround in the business is continuing.

The latest report from Baxter of the US leads brokers to suggest CSL is gaining market share at that company’s expense, though opinions remain divided on the value in CSL at current levels.

The quant boffins are out in force with their surprise predictions, Morgan Stanley looks at small caps while Merrill Lynch calls current FY11 forecasts “absurd”.

PanAust delivered a solid quarterly production report and with a number of growth options available brokers remain almost unanimously positive on the stock at current levels.

Brokers discuss healthcare while JP Morgan looks for surprises and RBS points out where $37bn in franking credits could be accessed.

Brokers are sticking to 24% upside targets for BHP.